Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Polypharmacy and medication deprescribing: A survey among multimorbid older adults in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Inconsistencies in dosage practice in children with overweight or obesity: A retrospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Clinical trial allocation in multinational pharmaceutical companies - a qualitative study on influential factors

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Mechanical and vasomotor properties of piglet isolated middle cerebral artery

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The chronobiology of migraine: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  2. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The kynurenine pathway (KP) is the main path for tryptophan metabolism, and it represents a multitude of potential sites for drug discovery in neuroscience, including pain, stroke, and epilepsy. L-kynurenine (LKYN), the first active metabolite in the pathway, emerges to be a prodrug targeting glutamate receptors. The safety, tolerability, pharmacokinetics, and pharmacodynamics of LKYN in humans have not been previously investigated. In an open-label, single ascending dose study, six participants received an intravenous infusion of 50, 100, and 150 µg/kg LKYN and new six participants received an intravenous infusion of 0.3, 0.5, 1, and 5 mg/kg LKYN. To compare the pharmacological effects between species, we investigated in vivo the vascular effects of LKYN in rats. In humans, LKYN was safe and well-tolerated at all dose levels examined. After infusion, LKYN plasma concentration increased significantly over time 3.23 ± 1.12 µg/mL (after 50 µg/kg), 4.04 ± 1.1 µg/mL (after 100 µg/kg), and 5.25 ± 1.01 µg/mL (after 150 µg/kg) (p ≤ 0.001). We observed no vascular changes after infusion compared with baseline. In rats, LKYN had no effect on HR and MAP and caused no dilation of dural and pial arteries. This first-in-human study of LKYN showed that LKYN was safe and well-tolerated after intravenous infusion up to 5 mg/kg over 20 minutes. The lack of change in LKYN metabolites in plasma suggests a relatively slow metabolism of LKYN and no or little feed-back effect of LKYN on its synthesis. The therapeutic potential of LKYN in stroke and epilepsy should be explored in future studies in humans.

Original languageEnglish
JournalPharmacology Research & Perspectives
Volume9
Issue number2
Pages (from-to)e00741
ISSN2052-1707
DOIs
Publication statusE-pub ahead of print - 2021

    Research areas

  • epilepsy, glutamat, kynurenic acid, migraine, stroke

ID: 65608408